Please assess the completion status of the following clinical trial:

Trial Title: Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Screening FEV1 between 40% and 100% predicted value for age, gender and height, in patients capable of properly performing the test;~* History of pulmonary exacerbation, defined as at least one (1) pulmonary exacerbation in the year prior to Screening which resulted in documented intravenous or Oral antibiotics;~* Patients are eligible independently of their history of pulmonary Pseudomonas aeruginosa (PsA) infection and their PsA status at screening;~* If taking Kalydeco® (ivacaftor), Orkambi® (ivacaftor/lumacaftor), Symdeko® (ivacaftor/tezacaftor) or other commercially available CFTR modulator products, patients must be taking it for a minimum of 3 months prior to screening if naïve to CFTR modulators and 1 month if switched from another CFTR modulator product and deemed to tolerate it;~* No change in CF and allowed systemic chronic therapy for a minimum of 5 weeks prior to randomization, of which 2 weeks minimum are prior to screening;~* Female patients of child bearing potential should be on highly effective contraceptive methods during the study;~* Male patients with spouse or partner of child bearing potential, or pregnant, are eligible if they use an appropriate method of contraception.~Exclusion Criteria:~* Pregnancy: due to the potential teratogenic effects of retinoids, pregnant women are NOT eligible;~* Breast milk feeding by study patient is NOT allowed;~* Clinically abnormal renal function: serum creatinine \> 132 μM (1.5 mg/dL);~* Clinically abnormal liver function: Total bilirubin \>1.5 x ULN (in the absence of demonstrated Gilbert's syndrome), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 2.5 x ULN;~* Patients with plasma retinol levels below 0.7 µM;~* Presence of nyctalopia or hemeralopia at enrolment, or any other serious retinal, ophthalmological condition;~* Presence of serious dermatological conditions at entry, including inflammatory or xerotic skin pathologies such as psoriasis or ichthyosis;~* Intake of chronic systemic steroids in the month prior to screening and during the study;~* History of acute infections (viral/bacterial/fungal) within 5 weeks prior to randomization, of which 2 weeks minimum are prior to screening, whether or not treated and resolved;~* Presence of infection with Burkholderia cepacia (including all species within the Burkholderia cepacia complex group, and Burkholderia gladioli) in the 12 months prior to screening;~* Patients with a confirmed diagnosis (as per the Cystic Fibrosis Foundation diagnostic criteria) of Allergic BronchoPulmonary Aspergillosis (ABPA) and actively being treated with corticosteroids and/or anti fungal agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LAU-7b (Type: EXPERIMENTAL): Active drug fenretinide (as LAU-7b capsules)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral capsule (as inactive capsules identical to active arm)

Based on this trial design, predict the completion outcome and termination type (if applicable).